Emerging systemic drugs in the treatment of plaque psoriasis

References

• Laws PM, Young HS. Current and emerging systemic treatment strategies for psoriasis. Drugs. 2012;72(14):1867–1880.
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–653.
   PubMed Web of Science ®Google Scholar
• Mahmood T, Zaghi D, Menter A. Emerging oral drugs for psoriasis. Expert Opin Emerg Drugs. 2015;20(2):209–220.
   PubMed Web of Science ®Google Scholar
• Scarpa R, Caso F, Costa L, et al. Psoriatic disease 10 years later. J Rheumatol. 2017;44(9):1298–1301. Canada2017.
   PubMed Web of Science ®Google Scholar
• Hu SCS, Lan CCE. 2017. Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment. Int J Mol Sci. 2017;18 (10):2211.
   Web of Science ®Google Scholar
• Bissonnette R, Bourcier M, Gooderham M, et al., Management of moderate to severe plaque psoriasis: the emerging role of IL-17 inhibition. J Cutan Med Surg. 2017;21(2_suppl): 2S–40S.
   PubMedGoogle Scholar
• Colgecen E, Celikbilek A, Keskin DT. cognitive impairment in patients with psoriasis: a cross-sectional study using the montreal cognitive assessment. Am J Clin Dermatol. 2016 Aug;17(4):413–419.
   PubMed Web of Science ®Google Scholar
• Horn EJ, Fox KM, Patel V, et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol. 2007 Dec;57(6):963–971.
   PubMed Web of Science ®Google Scholar
• Bowcock AM, Barker JN. Genetics of psoriasis: the potential impact on new therapies. J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S51–6.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009 Jul 30;361(5):496–509.
   PubMed Web of Science ®Google Scholar
• Calautti E, Avalle L, Poli V. Psoriasis: a STAT3-Centric View. Int J Mol Sci. 2018;19(1):E171.
   PubMed Web of Science ®Google Scholar
• Di Meglio P, Villanova F, Nestle F. Psoriasis [Text]. Cold Spring Harb Perspect Med. 2014;4(8):a015354.
   PubMed Web of Science ®Google Scholar
• Reich K, Rich P, Maari C, et al. Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. Br J Dermatol. 2019 Jul;181(1):88–95.
   PubMed Web of Science ®Google Scholar
• Gooderham M. Small molecules: an overview of emerging therapeutic options in the treatment of psoriasis. Skin Therapy Lett. 2013;18(7):1–4.
   PubMedGoogle Scholar
• Kimball AB, Leonardi C, Stahle M, et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol. 2014 Jul;171(1):137–147.
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005 Jun;152(6):1304–1312.
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005 Oct 15;21;366(9494):1367–1374.
   Web of Science ®Google Scholar
• Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007 Jan;56(1):31.e1-15.
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008 Jan;58(1):106–115.
   PubMed Web of Science ®Google Scholar
• Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1148–1158.
   PubMed Web of Science ®Google Scholar
• Al-Dabagh A, Al-Dabagh R, Davis SA, et al. Systemic corticosteroids are frequently prescribed for psoriasis. J Cutan Med Surg. 2014 May-Jun;18(3):195–199.
   PubMed Web of Science ®Google Scholar
• Gaspari AA, Tyring S. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. Dermatol Ther. 2015;28(4):179–193.
   PubMed Web of Science ®Google Scholar
• Bagel J, Gold LS. Combining topical psoriasis treatment to enhance systemic and phototherapy: a review of the literature. J Drugs Dermatol. 2017;16(12):1209–1222.
   PubMed Web of Science ®Google Scholar
• Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017 Apr;63(4):278–285.
   PubMed Web of Science ®Google Scholar
• Naldi L, Raho G. Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145–163.
   PubMed Web of Science ®Google Scholar
• Cheng J, Feldman SR. The cost of biologics for psoriasis is increasing. Drugs Context. 2014;3:212–266.
   Google Scholar
• Costa L, Del Puente A, Peluso R, et al. Small molecule therapy for managing moderate to severe psoriatic arthritis. Expert Opin Pharmacother. 2017 Oct;18(15):1557–1567..
   PubMed Web of Science ®Google Scholar
• Berekmeri A, Mahmood F, Wittmann M, et al. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018 Sep;14(9):719–730.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov NIHUSNLoM. Safety and efficacy of tofacitinib vs methotrexate in the Treatment of psoriatic arthritis 2019 [cited 2020 Jan 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03736161
   Google Scholar
• Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017 Apr;76(4):736–744.
   PubMed Web of Science ®Google Scholar
• Psoriasis drugs market: global Trends, share, growth, opportunity and 2022 [Internet]. Market watch: market watch; 2019.
   Google Scholar
• Rizvi S, Chaudhari K, Syed BA. The psoriasis drugs market. Nat Rev Drug Discov. 2015;14(11):745–746.
   PubMed Web of Science ®Google Scholar
• Schön MP, Erpenbeck L. The Interleukin-23/Interleukin-17 axis links adaptive and innate immunity in psoriasis. Front Immunol. 2018;9:1323.
   PubMedGoogle Scholar
• Tsai YC, Tsai TF. Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness. Ther Adv Musculoskelet Dis.
   Web of Science ®Google Scholar
• Mansouri B, Richards L, Menter A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1β inhibitor gevokizumab. Br J Dermatol. 2015;173(1):239–241.
   PubMed Web of Science ®Google Scholar
• Fiocco U, Accordi B, Martini V, et al. JAK/STAT/PKCdelta molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res. 2014 Jan;58(1):61–69.
   PubMed Web of Science ®Google Scholar
• Fiocco U, Martini V, Accordi B, et al. Ex vivo signaling protein mapping in T Lymphocytes in the psoriatic arthritis joints. J Rheumatol Suppl. 2015 Nov;93:48–52.
   PubMedGoogle Scholar
• Fiocco U, Martini V, Accordi B, et al. Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clin Rheumatol. 2015 Sep;34(9):1571–1580.
   PubMed Web of Science ®Google Scholar
• Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i43–i54.
   PubMed Web of Science ®Google Scholar
• Papp K, Gordon K, Thaci D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018 Oct 4;379(14):1313–1321.
   PubMed Web of Science ®Google Scholar
• Banerjee D, Zhao L, Wu L, et al. Small molecule mediated inhibition of RoRγ‐dependent gene expression and autoimmune disease pathology in vivo. Immunology. 2016;147:399–413.
   PubMed Web of Science ®Google Scholar
• Papp K, Merola J, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blind, placebo-controlled phase 2b study. A Am Acad Dermatol. 2018;79(2):277–286.
   PubMed Web of Science ®Google Scholar
• Bimekizumab positive results confirmed in second phase 3 psoriasis study [Internet]; 2019. [cited 2019 Dec 13]. Available from: https://www.prnewswire.com/news-releases/bimekizumab-positive-results-confirmed-in-second-phase-3-psoriasis-study-300958940.html
   Google Scholar
• Reichert J Anti-IL17 netakimab registered in Russia antibodysociety.org: antibody society; 2019. [cited 2019 Dec 24]. Available from: https://www.antibodysociety.org/anti-il17-netakimab-registered-in-russia/
   Google Scholar
• BIOCAD registered the first Russian original therapeutic monoclonal antibody: BIOCAD Biotechnology Company; 2019 [cited 2019 Dec 29]. Available from: https://biocadglobal.com/post/Russian_original_therapeutic_monoclonal_antibody
   Google Scholar
• Kubanov AABA, Samtsov AV, Khairutdinov VR, et al. Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis. Vestnik Dermatologii I Venerologii. 2019;95(2):15–28.
   Google Scholar
• Affibody. A study to evaluate ABY-035 in subjects with moderate-to-severe plaque psoriasis - full text view - clinicaltrials.gov nih U.S. National Library of Medicine. Clinicaltrials.gov; 2019 [cited 2019 Dec 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT03591887
   Google Scholar
• Affibody announces interim analysis in phase 2 psoriasis trial of ABY-035 [Internet]. 2019. Solna (Sweden): Affibody [cited 2019 Dec 10]. Available from: https://www.affibody.se/affibody-announces-interim-analysis-in-phase-2-psoriasis-trial-of-aby-035/
   Google Scholar
• Jovcevska I, Muyldermans S. The therapeutic potential of nanobodies. BioDrugs. 2020 Nov 4;34(1):11–26.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A phase 2b study of the efficacy, safety, and tolerability of M1095 in subjects with moderate to severe psoriasis: NIH National Library of Medicine; 2019 [cited 2019 Dec 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03384745
   Google Scholar
• Chiricozzi A, De Simone C, Fossati B, et al. Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential. Psoriasis (Auckl). 2019;9:29–35.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov NIHUSNLoM. Multiple ascending dose trial of MSB0010841 (Anti-IL17A/F Nanobody) in psoriasis subjects - study results. Clinicaltrials.gov; 2019 [cited 2019 Dec 23]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02156466
   Google Scholar
• ClinicalTrials.gov. Multi-dose study of SHR-1314 in subjects with moderate-to-severe plaque psoriasis - full text view - clinicaltrials.gov: NIH US National Library of Medicine clinicaltrials.gov; 2019 [cited 2019 Dec 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03463187
   Google Scholar
• Papp K, Godderham M, Jenkins R, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody. Br J Dermatol. 2019;180(6):1352–1360.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov NIHUSNLoM. Gevokizumab with standard of care anti-cancer therapies for metastatic colorectal, gastroesophageal, and renal cancers - full text view. Clinicaltrials.gov; 2019. [cited 2019 Dec 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT03798626
   Google Scholar
• Papp K, Menter M, Ramam M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2019;174(6):1266–1276.
   Google Scholar
• ClinicalTrials.gov NIHUSNLoM. A study to evaluate safety and efficacy of PF-06826647 for moderate to severe plaque psoriasis - full text view - clinicaltrials.gov 2020 [cited 2020 Jan 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT03895372
   Google Scholar
• Blair H. Dimethyl fumarate: A review in moderate to severe plaque psoriasis. Drugs. 2018;78(1):123–130.
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Ryan C, Kim R, et al. XP-23829, a novel fumaric acid ester, is efficacious in reducing psoriatic lesions: results from a phase 2 randomized controlled study. Skin J Cutaneous Medicine. 2017;1:s33.
   Google Scholar
• ClinicalTrials.gov NIHUSNLoM. A study to assess the efficacy and safety of XP23829 in subjects with moderate-to-severe chronic plaque-type psoriasis - full text view. Clinicaltrials.gov; 2020 [cited 2020 Jan 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT02173301
   Google Scholar
• Actelion’s ponesimod successful in mid-stage trial in patients with moderate to severe chronic plaque psoriasis - ponesimod to proceed to phase III clinical development in psoriasis; 2019. Actelion Pharmaceuticals Ltd. [cited 2020 Jan 5]. Available from: https://www.actelion.com/media/media-releases?newsId=1665730
   Google Scholar
• Yiu Z, Warren R. Novel oral therapies for psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2016;17(3):191–200.
   PubMed Web of Science ®Google Scholar
• Ecoeur F, Weiss J, Kaupmann K, et al. Antagonizing retinoic acid-related-orphan receptor gamma activity blocks the T Helper 17/Interleukin-17 Pathway leading to attenuated pro-inflammatory human keratinocyte and skin responses. Front Immunol. 2019;10:577.
   PubMed Web of Science ®Google Scholar
• Leavitt M Drug in development may one day pack the power of a biologic into a pill, according to early trial results National Psoriasis Foundation Advance Online: National Psoriasis Foundation Advance Online; 2016. [cited 2020 Jan 3]. Available from: https://www.psoriasis.org/advance/drug-development-may-one-day-pack-power-biologic-pill-according-early-trial-results
   Google Scholar
• ClinicalTrials.gov NIHUSNLoM. An ascending multiple dose study with VTP-43742 in healthy volunteers - full text view - clinicaltrials.gov; 2020. [cited 2020 Jan 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT03724292
   Google Scholar
• Inc AP. Study to evaluate the efficacy and safety of JTE-451 in subjects with moderate to severe plaque psoriasis - full text view - clinicaltrials.gov NIH U.S. National library of medicine. Clinicaltrials.gov; 2019. [cited 2020 Jan 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03832738
   Google Scholar
• Abbvie. A study to evaluate the pharmacokinetics, safety and tolerability of ABBV-157 in healthy volunteers and in participants with chronic plaque psoriasis - full text view - clinicaltrials.gov NIH U.S. National library of medicine. Clinicaltrials.gov; 2019. [cited 2020 Jan 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03922607
   Google Scholar
• Cohen S, Barer F, Itzhak I, et al. Inhibition of IL-17 and IL-23 in human keratinocytes by the A3 adenosine receptor agonist Piclidenoson. J Immunol Res. 2018;229(6):2310970. 2018;eCollection.
   Google Scholar
• Sivamani RK, Correa G, Ono Y, et al. Biological Therapy Of Psoriasis. Indian J Dermatol. 2010;55:161–170.
   PubMedGoogle Scholar
• O’Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase Inhibitors in autoimmune diseases. Ann Rheum Dis. 2013 Apr;72(2):ii111–5.
   PubMedGoogle Scholar
• Caso F, Del Puente A, Peluso R, et al. Emerging drugs for psoriatic arthritis. Expert Opin Emerg Drugs. 2016;21(1):69–79.
   PubMed Web of Science ®Google Scholar